Sign In
Buy CODX
$5.17
-1.05 (-16.88%)
At Close: Jun 03, 2026
Co-Diagnostics and CoSara Advance Ebola PCR Test Development and Co-Dx™ PCR Point-of-Care Platform Capabilities
09:00am, Tuesday, 02'nd Jun 2026
Dual-assay strategy designed to support outbreak response and surveillance efforts in affected regions Potential blood-based Ebola assay would represent an important expansion of Co-Dx™ PCR point-of
Is Co-Diagnostics National Security's Next Diagnostic Pick?
11:03am, Thursday, 28'th May 2026
A structural shift is underway in the biodefense landscape. The declaration of a Public Health Emergency of International Concern (PHEIC) by the World Health Organization on May 17, 2026, for the Bund
Co-Diagnostics Advances Ebola PCR Assay Development Strategy with Joint Venture CoSara
09:00am, Tuesday, 26'th May 2026
Joint development strategy has been developed to address international deployment requirements if current outbreak continues or expands globally SALT LAKE CITY, May 26, 2026 /PRNewswire/ -- Co-Diagnos
Co-Diagnostics Announces $3.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
10:54pm, Tuesday, 19'th May 2026
SALT LAKE CITY, May 19, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx", or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of m
Co-Diagnostics Develops Ebola Assay Strategy Following Recent Global Outbreak Alert
09:00am, Tuesday, 19'th May 2026
Recent pathogens illustrate need for improved situational awareness capabilities, such as those provided by the Co-Dx PCR point-of-care platform Follows outbreak of Ebola and WHO emergency declaration
Co-Diagnostics, Inc. (CODX) Q1 2026 Earnings Call Transcript
07:10pm, Thursday, 14'th May 2026
Co-Diagnostics, Inc. (CODX) Q1 2026 Earnings Call Transcript
Co-Diagnostics Reports First Quarter 2026 Financial Results
04:01pm, Thursday, 14'th May 2026
Advancing Global Commercialization Through CoSara Regulatory Progress and Regional Expansion Executing Clinical Strategy with Upper Respiratory Submission Preparation and TB Study Initiation Expanding
Lease execution highlights transition from approval to development and advances localized manufacturing strategy in the Kingdom of Saudi Arabia in accordance with Vision 2030 SALT LAKE CITY, May 8, 20
Co-Diagnostics Announces First Quarter 2026 Earnings Release Date and Webcast
09:00am, Thursday, 30'th Apr 2026
SALT LAKE CITY, April 30, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of
Co-Diagnostics Invited to Present at Stop TB Partnership Summit in Washington, D.C.
09:00am, Thursday, 16'th Apr 2026
MTB test on Co-Dx PCR platform* to be presented at roundtable with Stop TB Partnership, U.S. Department of State, and global stakeholders SALT LAKE CITY, April 16, 2026 /PRNewswire/ -- Co-Diagnostics,
Co-Diagnostics to Showcase Co-Dx PCR Platform and CE-IVD Solutions at ESCMID 2026 in Munich, Germany
09:00am, Tuesday, 14'th Apr 2026
Company to engage with global customers and distributors while expanding international commercial relationships SALT LAKE CITY, April 14, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (t
Co-Diagnostics Executives to Participate in European Trade Mission with Utah Governor and WTC Utah
09:00am, Thursday, 09'th Apr 2026
Trade mission itinerary of business, government, and industry briefings across Switzerland and Germany to include site visits to Roche Diagnostics, UBS, Zurich Innovation Park and more SALT LAKE CITY,
Co-Diagnostics, Inc. (CODX) Q4 2025 Earnings Call Transcript
02:42am, Wednesday, 01'st Apr 2026
Co-Diagnostics, Inc. (CODX) Q4 2025 Earnings Call Transcript
Co-Diagnostics Reports Full Year 2025 Financial Results
04:01pm, Tuesday, 31'st Mar 2026
Advancing Global Commercialization Strategy Through CoSara and CoMira Joint Ventures Progressing Clinical Pipeline and Regulatory Pathways for PCR Platform Strengthening Technology Leadership with AI
The near-term commencement of clinical studies is expected to align with recent WHO tuberculosis recommendations for near-point-of-care molecular testing and utilizing tongue swab samples New recommen
